Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm|Neoplasm Metastasis
Interventions: DRUG: Abemaciclib|DRUG: Fulvestrant|DRUG: Placebo
Sponsor: Eli Lilly and Company